CA-ESRI
17.12.2021 22:02:10 CET | Business Wire | Press release
The global population grew by almost two billion people during the last 20 years—nearly 30 percent. Such growth is not evenly distributed over time or across space: the extremes include Qatar growing by 400 percent and Lithuania losing 25 percent. And even within countries, the rate of growth varies. To support the need for up-to-date population data that reflects these shifts, WorldPop and Esri , the global leader in location intelligence, have partnered to include WorldPop's 1-km annual gridded demographic datasets in ArcGIS Living Atlas of the World. The data covers 241 countries, territories, and dependencies for the 2000–2020 period.
"These datasets are critical for measuring and monitoring the accompanying sociodemographic changes over time and properly informing and supporting environmental, health, and development applications at local, subnational, national, and regional levels," said Professor Andrew Tatem, Director of WorldPop at the University of Southampton. "In this context, comparable, multitemporal, and spatially explicit detailed population distribution datasets are a fundamental prerequisite for communicating the impacts of population growth."
ArcGIS Living Atlas of the World is Esri's evolving collection of ready-to-use and up-to-date authoritative content in the form of maps, apps, and data layers—all accessible via a web browser and most Esri products.
"Having the WorldPop 1-km gridded demographic datasets available as imagery layers in ArcGIS Living Atlas of the World provides unprecedented convenience to query and analyze population anywhere on Earth," said Charlie Frye, Esri chief cartographer. "That these datasets no longer need to be downloaded or preassembled prior to use will result in substantial time and cost savings for any organization needing to understand recent population changes."
Queries can include the entire 21-year history of population changes for any group, including births and five-year age cohorts. The results of these queries can be spatiotemporally analyzed using Esri's ArcGIS software to find patterns. Multitemporal datasets depict grid cell level spatial distribution of total population, age, and sex cohorts and population density.
"The age and sex gridded datasets provide invaluable information about the spatial and temporal distribution of specific demographic groups, such as children, seniors, and women of childbearing age, which are well-known to be more vulnerable than others, and thus should be explicitly considered in decision- and policy-making processes," said Dr. Alessandro Sorichetta, Associate Professor in Applied Geospatial Research at WorldPop.
The 1-km raster layers, curated by the WorldPop Spatial Data Infrastructure Team led by Dr Maksym Bondarenko, are available in ArcGIS Living Atlas of the World for population per grid cell , population density per grid cell , and population by age and sex per grid cell .
To learn more about ArcGIS Living Atlas of the World and other Esri population data layers, please visit go.esri.com/livingatlas .
About WorldPop
WorldPop, initiated in October 2013 at the University of Southampton, develops methods and applications to produce open and high-resolution geospatial datasets on population distribution, demographics, and dynamics, with a focus mainly on low- and middle-income countries, to support development, disaster-response, and health applications. WorldPop research activities are designed with full open access and operational application in mind, using transparent, fully documented and peer-reviewed methods, to produce easily updatable outputs with accompanying metadata and, where possible, measures of uncertainty. WorldPop's work contributes to and benefits from direct engagement with multiple national statistical offices, national and international agencies, universities, research centers, and large international humanitarian donors, producing rapid and strong impacts from its research. WorldPop's population datasets and analyses inform several regional and global flagship reports and are the default geospatial demographic datasets used by many governments, international organizations, UN agencies, and private companies around the World. To learn more, visit our website and/or follow us on Twitter .
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com .
Copyright © 2021 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211217005617/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom